Valuation : Orthocell Limited

Market Cap 197M 142M 122M 115M 105M 196M 13.54B 1.37B 527M 6.87B 532M 520M 21.81B P/E 2027 *
-14.5x
P/E 2028 * -36.3x
Enterprise Value 169M 122M 105M 98.6M 89.83M 168M 11.62B 1.17B 452M 5.89B 456M 446M 18.72B EV / Sales 2027 *
8.92x
EV / Sales 2028 * 4.55x
Free-Float
83.41%
Yield 2027 *
-
Yield 2028 * -
1 day-1.38%
1 week-0.69%
Current month-6.54%
1 month-10.62%
3 months-4.03%
6 months-12.80%
Current year-34.10%
1 week 0.72
Extreme 0.715
0.74
1 month 0.72
Extreme 0.715
0.86
Current year 0.7
Extreme 0.7
1.16
1 year 0.7
Extreme 0.7
1.6
3 years 0.32
Extreme 0.322
1.79
5 years 0.3
Extreme 0.3
1.79
10 years 0.1
Extreme 0.105
1.79
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 21/03/2006
Chief Executive Officer 60 21/03/2006
Director of Finance/CFO - 01/08/2025
Director TitleAgeSince
Director/Board Member 60 21/03/2006
Director/Board Member 60 08/03/2023
Chairman - 01/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
7/20/26 A Buy

Chairman

15,430 0.0057%
7/17/26 A Buy 11,573 0.0043%
7/17/26 A Buy

Director

16,603 0.0061%
Change 5-day change 1-year change 3-year change Capi.($)
-1.38%-0.69%-35.59%+95.89% 142M
-0.41%-2.47%+26.57%+16.38% 224B
-2.11%-4.98%+4.12%-19.26% 144B
+2.04%-2.53%-19.89%+20.87% 125B
-4.14%-8.20%-59.04%-19.99% 65.16B
-0.70%-1.00%-20.42%-13.99% 50.05B
+0.68%-3.35%+10.85%+17.15% 49.67B
-1.13%-4.57%+15.31%+25.55% 40.81B
-0.78%-2.88%+37.06%+52.38% 39.77B
-1.82%-9.20%+110.78%+27.10% 30.96B
Average -0.82%-3.24%+6.97%+20.21% 76.93B
Weighted average by Cap. -0.70%-3.34%+6.83%+8.23%

Financials

2027 *2028 *
Net sales 19M 13.63M 11.72M 11.06M 10.07M 18.83M 1.3B 132M 50.68M 661M 51.17M 50.05M 2.1B 38M 27.25M 23.44M 22.11M 20.14M 37.66M 2.61B 263M 101M 1.32B 102M 100M 4.2B
Net income -13M -9.32M -8.02M -7.56M -6.89M -12.88M -891M -90.1M -34.68M -452M -35.01M -34.24M -1.44B -5.25M -3.77M -3.24M -3.06M -2.78M -5.2M -360M -36.38M -14M -183M -14.14M -13.83M -580M
Net Debt -28M -20.08M -17.27M -16.29M -14.84M -27.75M -1.92B -194M -74.68M -974M -75.41M -73.76M -3.09B -24.65M -17.68M -15.2M -14.34M -13.07M -24.43M -1.69B -171M -65.75M -857M -66.38M -64.93M -2.72B
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-
Date Price Change Volume
11/09/26 A$0.7150 -1.38% 73,837
10/09/26 A$0.7250 0.00% 244,100
09/09/26 A$0.7250 -0.68% 173,708
08/09/26 A$0.7300 0.00% 34,104
07/09/26 A$0.7300 +1.39% 98,362
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7250AUD
Average target price
1.140AUD
Spread / Average Target
+57.24%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!